Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Author index

Page Path
HOME > Browse articles > Author index
Search
Sang Young Rho 2 Articles
Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer
Eun Kyoung Jeon, Sook Hee Hong, Tae Hee Kim, Seung Eun Jung, Ji Chan Park, Hye-Sung Won, Yoon-Ho Ko, Sang Young Rho, Young Seon Hong
Cancer Res Treat. 2011;43(3):148-153.   Published online September 30, 2011
DOI: https://doi.org/10.4143/crt.2011.43.3.148
AbstractAbstract PDFPubReaderePub
PURPOSE
The purpose of this study was to evaluate efficacy and toxicity of irinotecan, leucovorin and 5-fluorouracil (FOLFIRI) as second-line treatment after failure of oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) for advanced gastric cancer.
MATERIALS AND METHODS
Patients who received modified FOLFOX-4 as first-line treatment and then received sequential modified FOLFIRI for disease progression were included in this study. The modified FOLFIRI regimen consisted of irinotecan 150 mg/m2 in a 90-minute intravenous infusion on day 1, leucovorin (LV) 20 mg/m2 and 5-fluorouracil (5-FU) 400 mg/m2 as a bolus followed by 600 mg/m2 as a 22-hour infusion on days 1 and 2 with the same dose of 5-FU/LV of modified FOLFOX-4 every 2 weeks.
RESULTS
A total of 32 patients received 126 courses of FOLFIRI chemotherapy. No complete response was achieved. Three patients (9.4%; 95% confidence interval [CI], 0 to 20.1%) achieved partial response, whereas 11 (34.4%; 95% CI, 17.0 to 51.8%) patients showed stable disease. Disease control rate (complete response, partial responses and stable diseases) was 43.8% (95% CI, 25.6 to 61.9%) and median follow up duration was 11.3 months (range, 2.23 to 37.9 months). Median time to progression was 2 months (95% CI, 1.49 to 2.51 months), and median overall survival from the start of FOLFIRI was 5.84 months (95% CI, 4.34 to 7.34 months). Toxicities were tolerable.
CONCLUSION
Modified FOLFIRI as second-line chemotherapy after failure of the modified FOLFOX-4 in advanced gastric cancer was tolerable but showed a lower response rate. Further study about retrying 5-FU/LV with irinotecan after failure of the 5-FU/LV combined regimen is necessary in advanced gastric cancer.

Citations

Citations to this article as recorded by  
  • Current therapeutic options for gastric adenocarcinoma
    C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
    Saudi Journal of Biological Sciences.2021; 28(9): 5371.     CrossRef
  • Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis
    Ana Fernández Montes, Carlos López López, Guillem Argilés Martínez, David Páez López, Ana María López Muñoz, Beatriz García Paredes, David Gutiérrez Abad, Carmen Castañón López, Paula Jiménez Fonseca, Javier Gallego Plazas, María Carmen López Doldán, Eva
    The Oncologist.2019; 24(8): e687.     CrossRef
  • Thymineless Death by the Fluoropyrimidine Polymer F10 Involves Replication Fork Collapse and Is Enhanced by Chk1 Inhibition
    Chinnadurai Mani, Sachin Pai, Cinta Maria Papke, Komaraiah Palle, William H. Gmeiner
    Neoplasia.2018; 20(12): 1236.     CrossRef
  • Effect of FOLFOX4 combined with Brucea javanica emulsion on VEGF in patients with gastric cancer
    Zheng Chen, Zhenyu Zhou, Zhigang Hu, Qiaodong Xu, Jie Wang
    Oncology Letters.2017;[Epub]     CrossRef
  • Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program
    Markus Moehler, Irina Gepfner-Tuma, Annett Maderer, Peter C. Thuss-Patience, Joern Ruessel, Susanna Hegewisch-Becker, Hansjochen Wilke, Salah-Eddin Al-Batran, Mohammad-Reza Rafiyan, Florian Weißinger, Hans-Joachim Schmoll, Frank Kullmann, Ludwig Fischer v
    BMC Cancer.2016;[Epub]     CrossRef
  • 5-Fluorouracil derivatives: a patent review (2012 – 2014)
    Esmeralda Carrillo, Saúl Abenhamar Navarro, Alberto Ramírez, María Ángel García, Carmen Griñán-Lisón, Macarena Perán, Juan Antonio Marchal
    Expert Opinion on Therapeutic Patents.2015; 25(10): 1131.     CrossRef
  • Efficacy and Safety of FOLFIRI as Second-line Chemotherapy in Advanced Gastric Cancer
    Sung Chul Park, Hoon Jai Chun
    The Korean Journal of Gastroenterology.2015; 66(1): 1.     CrossRef
  • Efficacy and Safety of FOLFIRI after Failure of FOLFOX-4 in Advanced Gastric Cancer
    Hye Jung Kwon, Moo In Park, Seun Ja Park, Won Moon, Sung Eun Kim, Hae Won Lee, Youn Jung Choi, Jae Hyun Kim
    The Korean Journal of Gastroenterology.2015; 66(1): 10.     CrossRef
  • FOLFIRI as Second-line Chemotherapy after Failure of FOLFOX4 in Advanced Colorectal Cancer: A Korean Single-center Experience
    Jae Hyun Kim, Seun Ja Park, Moo In Park, Won Moon, Sung Eun Kim, Ki Hwan Ku, Sung Eun Song, Je Hun Kim
    The Korean Journal of Gastroenterology.2014; 63(1): 18.     CrossRef
  • 5-Fluorouracil derivatives: a patent review
    Pablo Álvarez, Juan Antonio Marchal, Houria Boulaiz, Esmeralda Carrillo, Celia Vélez, Fernando Rodríguez-Serrano, Consolación Melguizo, Jose Prados, Roberto Madeddu, Antonia Aranega
    Expert Opinion on Therapeutic Patents.2012; 22(2): 107.     CrossRef
  • Outcomes of Third-Line Docetaxel-Based Chemotherapy in Advanced Gastric Cancer Who Failed Previous Oxaliplatin-Based and Irinotecan-Based Chemotherapies
    Min Jeong Lee, In Gyu Hwang, Joung-Soon Jang, Jin Hwa Choi, Byeong-Bae Park, Myung Hee Chang, Seung Tae Kim, Se Hoon Park, Myoung Hee Kang, Jung Hun Kang
    Cancer Research and Treatment.2012; 44(4): 235.     CrossRef
  • Irinotecan, leucovorin and 5-fluorouracil (modified FOLFIRI) as salvage chemotherapy for frail or elderly patients with advanced gastric cancer
    JUNG HAN KIM, HYEONG SU KIM, A RUM HAN, IN HO MOH, DOO CHEOL CHUNG, DAE RO CHOI, HYUN JOO JANG, JIN BAE KIM, DAE HYUN YANG, SOON IL LEE, DAE YOUNG ZANG
    Oncology Letters.2012; 4(4): 751.     CrossRef
  • 11,480 View
  • 83 Download
  • 12 Crossref
Close layer
Autologous Stem Cell Transplantation using a Modified TAM Conditioning Regimen for Clinically Aggressive Non-Hodgkin's Lymphoma
Sook Hee Hong, Young Seon Hong, In Sook Woo, Yoon Ho Koh, Sang Young Rho, Ji Yean Peak, Myung Ah Lee, Byoung Yong Shim, Jae Ho Byun, Ji Chan Park, Jong Wook Lee, Woo Sung Min, Chun Choo Kim
Cancer Res Treat. 2007;39(2):54-60.   Published online June 30, 2007
DOI: https://doi.org/10.4143/crt.2007.39.2.54
AbstractAbstract PDFPubReaderePub
Purpose

High-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT) have been used for the treatment of clinically aggressive non-Hodgkin's lymphoma (NHL). However, the superiority of specific conditioning regimens has not yet been established. The present study evaluated the efficacy and toxicity of a conditioning regimen involving fractionated total body irradiation (TBI), and the use of Ara-C and melphalan (TAM) for clinically aggressive NHL.

Materials and Methods

Between March 2002 and December 2004, 31 patients with aggressive NHL received fractionated TBI with a dose of 12 Gy over 3 days, and were administered 9 g/m2 Ara-C and 100 mg/m2 melphalan followed by autologous peripheral blood stem Cell Transplantation at the Catholic Hematopoietic Stem cell transplantation Center Korea. Patients that responded to first line chemotherapy and achieved complete remission (CR), or were in a first sensitive relapse were defined as having less advanced disease, while the other patients were defined as having more advanced disease.

Results

Objective responses were obtained in 24 of 31 patients (77.4%), comprising complete remission in 19 patients (61.3%) and partial remission in 5 (16.1%) patients. The median follow-up time was 28 months (range 1~62 months). At 3 years, the overall survival and event-free survival (EFS) rates were 62.3% and 47.3%, respectively. Patients with less advanced disease and more advanced disease showed 3-year EFS rates of 73.3% and 22.5 %, respectively (p=0.006). Early (within the first 100 days) treatment-related mortality occurred in 3 (9.7%) patients. Of the 31 total patients, 15 (48.4%) developed grade 3 mucositis, 22 (70.9%) developed neutropenic fever, and two (6.5%) developed interstitial pneumonia syndrome>grade 3.

Conclusion

The modified TAM conditioning regimen and ASCT appear to be a feasible treatment regimen for clinically aggressive NHL, particularly for patients with less advanced disease.

Citations

Citations to this article as recorded by  
  • Comparison of regional arterial chemotherapy and systemic intravenous chemotherapy for advanced pancreatic cancer: a systematic review and meta-analysis
    Chengqing Li, Wenyi Guo, Shihong Chen, Jianwei Xu, Feng Li, Lei Wang
    Journal of Pancreatology.2022; 5(2): 49.     CrossRef
  • 9,608 View
  • 55 Download
  • 1 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP